GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DLBS1033

Company
Dexa Medica Group
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01378585

    Safety and Efficacy of DLBS1033 in Healthy Subjects

    Not yet reported Dexa Medica Group 20 participants Est. completion 2011-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01694537

    The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers

    Not yet reported Indonesia University 21 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01790997

    Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

    Not yet reported Dexa Medica Group 126 participants Est. completion 2013-12 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT01865474

    Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Dexa Medica Group 122 participants Est. completion 2016-06 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01905878

    Biological Half Life of DLBS1033 in Healthy Volunteers

    Not yet reported, Not yet reported Indonesia University 14 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Healthy Condition
    View official trial listing →
  • Terminated NCT NCT02133521

    DLBS1033 for Acute Ischemic Stroke Patients

    Not yet reported, Not yet reported Dexa Medica Group 80 participants Est. completion 2023-04-21 10 sites Stand-alone
    Cardiovascular disease Other conditions: Partial Anterior Circulation Infarct, Lacunar Anterior Circulation Infarct
    View official trial listing →
  • Terminated NCT NCT02145988

    DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease

    Not yet reported, Not yet reported Dexa Medica Group 11 participants Est. completion 2018-07 2 sites Stand-alone
    Other conditions: Diabetes, Peripheral Arterial Disease
    View official trial listing →
  • Withdrawn NCT NCT02146664

    DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

    Not yet reported, Not yet reported Dexa Medica Group Est. completion 2018-03 2 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT02362984

    DLBS1033 for the Treatment of Acute Ischemic Stroke

    Not yet reported Dexa Medica Group 9 participants Est. completion 2017-04 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT02976701

    Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

    Not yet reported, Not yet reported Dexa Medica Group 23 participants Est. completion 2023-03 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT04425590

    The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

    Not yet reported, Not yet reported Duta Wacana Christian University 180 participants Est. completion 2020-08 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT07075289

    Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

    Not yet reported Universitas Sebelas Maret 44 participants Est. completion 2024-12-27 1 site Stand-alone
    Other conditions: Benign Paroxysmal Positional Vertigo (Disorder)
    View official trial listing →
  • Completed NCT NCT07121569

    Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes

    Not yet reported Universitas Sebelas Maret 52 participants Est. completion 2025-03-13 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07475065

    The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

    Not yet reported, Not yet reported Universitas Sebelas Maret 34 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Diabetic Polyneuropathy, Peripheral Nervous System Diseases, Peripheral Neuropathy, Diabetes Mellitus
    View official trial listing →
  • Not yet recruiting NCT NCT07683598

    DLBS1033 as Adjunctive Therapy for Patients With Diabetic Neuropathy

    Not yet reported RS H Adam Malik 80 participants Est. completion 2027-03-01 1 site Stand-alone
    Other conditions: Diabetic Neuropathy
    View official trial listing →
  • Completed NCT NCT07684625

    THE EFFECT OF LUMBRICUS RUBELLUS DLBS1033 EXTRACT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Not yet reported Universitas Sebelas Maret 60 participants Est. completion 2026-06-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.